The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Resolving conflict of interest The Joint Task Force on Practice Parameters (JTFPP) is
committed to ensuring that all guidelines are based on the best scientific evidence at the …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

During the past decade, immunotherapies have made a major impact on the treatment of
diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and …

Severe cutaneous adverse reactions (SCARs), which include Stevens–Johnson syndrome
and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (also …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …